249 related articles for article (PubMed ID: 22013098)
1. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes.
Xiao Y; Xu A; Law LS; Chen C; Li H; Li X; Yang L; Liu S; Zhou Z; Lam KS
J Clin Endocrinol Metab; 2012 Jan; 97(1):E54-8. PubMed ID: 22013098
[TBL] [Abstract][Full Text] [Related]
2. Dynamic change of serum FGF21 levels in response to glucose challenge in human.
Lin Z; Gong Q; Wu C; Yu J; Lu T; Pan X; Lin S; Li X
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1224-8. PubMed ID: 22539584
[TBL] [Abstract][Full Text] [Related]
3. Common autoimmune biomarkers, thyroid hormonal abnormalities, and beta cells dysfunction in patients with latent autoimmune diabetes in adults with type II diabetes mellitus.
Yousefzadeh G; Gozashti M; Najafipour H; Gholamhosseinian NA; Bahramnejad A; Shokouhi M
Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S52-5. PubMed ID: 27094870
[TBL] [Abstract][Full Text] [Related]
4. [Latent autoimmune diabetes in adults(LADA): part of the clinical spectrum of type-1 diabetes mellitus of autoimmune origin].
Pánczél P; Hosszúfalusi N; Bornemisza B; Horváth L; Jánoskuti L; Füst G; Rajczy K; Vatay A; Prohászka Z; Madácsy L; Luczay A; Blatniczky L; Halmos T; Körner A; Szilvási I; Romics L
Orv Hetil; 2001 Nov; 142(46):2571-8. PubMed ID: 11770176
[TBL] [Abstract][Full Text] [Related]
5. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques.
An SY; Lee MS; Yi SA; Ha ES; Han SJ; Kim HJ; Kim DJ; Lee KW
Diabetes Res Clin Pract; 2012 May; 96(2):196-203. PubMed ID: 22293928
[TBL] [Abstract][Full Text] [Related]
6. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria.
Lee CH; Hui EY; Woo YC; Yeung CY; Chow WS; Yuen MM; Fong CH; Xu A; Lam KS
J Clin Endocrinol Metab; 2015 Apr; 100(4):1368-75. PubMed ID: 25625802
[TBL] [Abstract][Full Text] [Related]
7. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects.
Li H; Bao Y; Xu A; Pan X; Lu J; Wu H; Lu H; Xiang K; Jia W
J Clin Endocrinol Metab; 2009 Jun; 94(6):2151-6. PubMed ID: 19318452
[TBL] [Abstract][Full Text] [Related]
8. Glutamic acid decarboxylase 65 autoantibody levels discriminate two subtypes of latent autoimmune diabetes in adults.
Li X; Yang L; Zhou Z; Huang G; Yan X
Chin Med J (Engl); 2003 Nov; 116(11):1728-32. PubMed ID: 14642146
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Circulating Fibroblast Growth Factor 21 in Subjects with and without Type 2 Diabetes.
Lu J; Yu H; Mo Y; Ma X; Hao Y; Lu W; Li H; Bao Y; Zhou J; Jia W
PLoS One; 2015; 10(11):e0142207. PubMed ID: 26540514
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.
Mraz M; Bartlova M; Lacinova Z; Michalsky D; Kasalicky M; Haluzikova D; Matoulek M; Dostalova I; Humenanska V; Haluzik M
Clin Endocrinol (Oxf); 2009 Sep; 71(3):369-75. PubMed ID: 19702724
[TBL] [Abstract][Full Text] [Related]
11. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients.
Chiu HK; Tsai EC; Juneja R; Stoever J; Brooks-Worrell B; Goel A; Palmer JP
Diabetes Res Clin Pract; 2007 Aug; 77(2):237-44. PubMed ID: 17234296
[TBL] [Abstract][Full Text] [Related]
12. Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus.
Taniguchi H; Nirengi S; Ishihara K; Sakane N
PLoS One; 2022; 17(2):e0263774. PubMed ID: 35192641
[TBL] [Abstract][Full Text] [Related]
13. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently.
Li X; Fan X; Ren F; Zhang Y; Shen C; Ren G; Sun J; Zhang N; Wang W; Ning G; Yang J
Diabetes Res Clin Pract; 2011 Jul; 93(1):10-6. PubMed ID: 21596453
[TBL] [Abstract][Full Text] [Related]
14. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels.
Cuevas-Ramos D; Almeda-Valdes P; Gómez-Pérez FJ; Meza-Arana CE; Cruz-Bautista I; Arellano-Campos O; Navarrete-López M; Aguilar-Salinas CA
Eur J Endocrinol; 2010 Sep; 163(3):469-77. PubMed ID: 20566587
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of LADA and frequency of GAD antibodies in diabetic patients with end-stage renal disease and dialysis treatment in Austria.
Biesenbach G; Auinger M; Clodi M; Prischl F; Kramar R;
Nephrol Dial Transplant; 2005 Mar; 20(3):559-65. PubMed ID: 15671073
[TBL] [Abstract][Full Text] [Related]
16. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21.
Iglesias P; Selgas R; Romero S; Díez JJ
Eur J Endocrinol; 2012 Sep; 167(3):301-9. PubMed ID: 22740503
[TBL] [Abstract][Full Text] [Related]
17. Serum FGF21 and RBP4 levels in patients with chronic hepatitis C.
Kukla M; Berdowska A; Stygar D; Gabriel A; Mazur W; Łogiewa-Bazger B; Sobala-Szczygieł B; Bułdak RJ; Rokitka M; Zajęcki W; Kępa L; Sawczyn T; Zwirska-Korczala K
Scand J Gastroenterol; 2012 Sep; 47(8-9):1037-47. PubMed ID: 22670657
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD38 autoantibodies: characterisation in new-onset type I diabetes and latent autoimmune diabetes of the adult (LADA) and comparison with other islet autoantibodies.
Mallone R; Ortolan E; Pinach S; Volante M; Zanone MM; Bruno G; Baj G; Lohmann T; Cavallo-Perin P; Malavasi F
Diabetologia; 2002 Dec; 45(12):1667-77. PubMed ID: 12488956
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.
Li H; Fang Q; Gao F; Fan J; Zhou J; Wang X; Zhang H; Pan X; Bao Y; Xiang K; Xu A; Jia W
J Hepatol; 2010 Nov; 53(5):934-40. PubMed ID: 20675007
[TBL] [Abstract][Full Text] [Related]
20. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.
Ong KL; Rye KA; O'Connell R; Jenkins AJ; Brown C; Xu A; Sullivan DR; Barter PJ; Keech AC;
J Clin Endocrinol Metab; 2012 Dec; 97(12):4701-8. PubMed ID: 23144467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
